Satellos Bioscience Future Growth
Future criteria checks 0/6
Satellos Bioscience's earnings are forecast to decline at 13.9% per annum. EPS is expected to decline by 2.8% per annum.
Key information
-13.9%
Earnings growth rate
-2.8%
EPS growth rate
Biotechs earnings growth | 24.2% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 30 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -32 | N/A | N/A | 2 |
12/31/2025 | N/A | -28 | N/A | N/A | 2 |
12/31/2024 | N/A | -32 | N/A | N/A | 2 |
3/31/2024 | N/A | -21 | -20 | -20 | N/A |
12/31/2023 | N/A | -16 | -15 | -15 | N/A |
9/30/2023 | N/A | -14 | -10 | -10 | N/A |
6/30/2023 | N/A | -13 | -8 | -8 | N/A |
3/31/2023 | N/A | -11 | -5 | -5 | N/A |
12/31/2022 | N/A | -11 | -6 | -6 | N/A |
9/30/2022 | N/A | -9 | -6 | -6 | N/A |
6/30/2022 | N/A | -18 | -7 | -7 | N/A |
3/31/2022 | N/A | -17 | -7 | -7 | N/A |
12/31/2021 | N/A | -16 | -5 | -5 | N/A |
9/30/2021 | N/A | -13 | -5 | -5 | N/A |
6/30/2021 | 0 | -2 | -2 | -2 | N/A |
3/31/2021 | N/A | -2 | -1 | -1 | N/A |
12/31/2020 | N/A | -2 | -2 | -2 | N/A |
12/31/2019 | 0 | -2 | -2 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MSCL.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MSCL.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MSCL.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if MSCL.F's revenue is forecast to grow faster than the US market.
High Growth Revenue: MSCL.F is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MSCL.F's Return on Equity is forecast to be high in 3 years time